NEW YORK (TheStreet) -- Shares of Actavis (ACT) are slightly higher on Tuesday, as analysts at Goldman Sachs place the stock on its conviction buy list and assigned a price target of $365. 

If the analysts are correct and the company does earn $24 per share in 2017, the stock has much more upside, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Mad Dash" segment. 

The stock has also traded well since its secondary offering and the company's acquisition of Allergan (AGN - Get Report) could be highly accretive, he added. 

"If they can monetize Allergan the way I think it can," the stock is going much higher, Cramer said. 

Actavis CEO Brenton Saunders is "extraordinary," Cramer said, adding that the company will continue to benefit from the many different uses of Botox

ACT Chart
Actavis ACT data by YCharts

Cramer turned his attention to MGM Resort International (MGM - Get Report), as shares soared 9% after Land and Buildings, an activist investment firm, said there's 70% upside in the stock citing "substantial real estate value." The firm suggested MGM Resort should convert to a REIT. 

Many of the casino stocks have been trading lower due to having exposure to Macau, Cramer said. However, MGM Resort has the least exposure to the region compared with its peers, he added. 

"So I don't think this is a bad call at all," he concluded. Cramer did say he would avoid stocks that have high exposure to Macau, such as Wynn Resorts (WYNN - Get Report). 

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.